CryoPort/$CYRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CryoPort
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
Ticker
$CYRX
Sector
Primary listing
Employees
1,098
Headquarters
Website
CryoPort Metrics
BasicAdvanced
$528M
7.80
$1.35
1.63
-
Price and volume
Market cap
$528M
Beta
1.63
52-week high
$11.44
52-week low
$4.58
Average daily volume
690K
Financial strength
Current ratio
16.236
Quick ratio
15.237
Long term debt to equity
43.502
Total debt to equity
44.34
Interest coverage (TTM)
-19.61%
Profitability
EBITDA (TTM)
-22.688
Gross margin (TTM)
44.95%
Net profit margin (TTM)
31.67%
Operating margin (TTM)
-23.02%
Effective tax rate (TTM)
-3.97%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-4.21%
Return on equity (TTM)
-9.19%
Valuation
Price to earnings (TTM)
7.798
Price to revenue (TTM)
2.207
Price to book
1.03
Price to tangible book (TTM)
1.5
Price to free cash flow (TTM)
-13.915
Free cash flow yield (TTM)
-7.19%
Free cash flow per share (TTM)
-0.757
Growth
Revenue change (TTM)
24.93%
Earnings per share change (TTM)
-136.73%
3-year revenue growth (CAGR)
1.19%
3-year earnings per share growth (CAGR)
-39.68%
What the Analysts think about CryoPort
Analyst ratings (Buy, Hold, Sell) for CryoPort stock.
Bulls say / Bears say
Total revenue from continuing operations for Q2 2025 grew 14% year-over-year to $45.5 million, showing strong demand for Cryoport’s services. (SEC)
Gross margin improved to 47.0% in Q2 2025 from 44.5% in Q2 2024, reflecting better operational efficiency. (SEC)
Cryoport finalized the sale of its CRYOPDP specialty courier business to DHL in a deal valued in the high hundreds of millions of euros, strengthening its cash position and expanding its strategic partnerships. (Reuters)
Life Sciences Products revenue rose just 7.8% in Q2 2025, well below the 21% growth seen in Life Sciences Services, showing weakness in the product division. (SEC)
Despite higher revenue, adjusted EBITDA was still negative at $0.9 million in Q2 2025, highlighting the company remains unprofitable. (The Motley Fool)
As of March 31, 2025, 76.6% of supported clinical trials were located in the Americas, leaving Cryoport vulnerable to a U.S. market downturn. (NASDAQ)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
CryoPort Financial Performance
Revenues and expenses
CryoPort Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CryoPort stock?
CryoPort (CYRX) has a market cap of $528M as of October 21, 2025.
What is the P/E ratio for CryoPort stock?
The price to earnings (P/E) ratio for CryoPort (CYRX) stock is 7.8 as of October 21, 2025.
Does CryoPort stock pay dividends?
No, CryoPort (CYRX) stock does not pay dividends to its shareholders as of October 21, 2025.
When is the next CryoPort dividend payment date?
CryoPort (CYRX) stock does not pay dividends to its shareholders.
What is the beta indicator for CryoPort?
CryoPort (CYRX) has a beta rating of 1.63. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.